Purpose: To understand the extent to which metastatic colorectal cancer (mCRC) patients receive education on the prevention and management associated with skin rash following Vectibix treatment. Furthermore, to investigate how this adverse event affects a patient's quality of life (QoL) and influences their treatment decisions.
Methods: A cross-sectional survey was administered to 200 mCRC patients (100 Vectibix users and 100 Vectibix non-users).